Shionogi & Co., Ltd. Announces Initiation of a Global Late Phase 2 Clinical Trial of Investigational Redasemtide in Patients with Acute Ischemic Stroke

You are about to leave https://www.shionogi.com/us/. If you wish to access one of our Group websites from another country, click Proceed. Medical practices and regulations can be different from one country to another. As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country. Please note that the Privacy Policy and Terms of Use may vary on different country sites within the Shionogi Group.